Chromadex Corp reports results for the quarter ended in September - Earnings Summary

Niagen Bioscience

02/11/2022 21:02

* Chromadex Corp  CDXC.OQ  reported a quarterly adjusted
loss of 4
cents​​ per share for the quarter ended in September. The mean
expectation of six analysts for the quarter was for a loss of 6
cents per share.
    * Revenue fell 1.4% to $17.06 million from a year ago;
analysts
expected $18.69 million. 
    * Chromadex Corp's reported EPS for the quarter was a loss
of 1
cent​.
    * The mean earnings estimate of analysts had risen by
about 11.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Chromadex Corp shares had risen by 33.3% this quarter and
lost 56.1% so far this year.
    * The company reported a quarterly loss of $985 thousand.
    * Wall Street's median 12-month price target for Chromadex
Corp is
$6.25 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
2 at 09:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.06          -0.04          Beat
 Jun. 30 2022      -0.08          -0.09          Missed
 Mar. 31 2022      -0.09          -0.11          Missed
 Dec. 31 2021      -0.10          -0.08          Beat